Scandinavian ChemoTech AB

Equities

CMOTEC B

SE0009242654

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-16 EDT			5-day change	1st Jan Change
1.86 ^SEK	-2.62%		-15.45%	-31.11%

07-11	Scandinavian Chemotech Announces Clinical Trial Progress	CI
06-04	Scandinavian Chemotech AB Provides Sales Results for the Second Quarter of Fiscal Year 2024	CI

Scandinavian ChemoTech Receives Its First Order from Horizon Medical Technologies

January 17, 2020 at 08:46 am

Scandinavian ChemoTech received its first order worth €3.300 from their new distributor Horizon Medical Technologies in India. The distribution agreement was signed in December 2019 and the order placed is for treatment kits dedicated to Horizons launch of IQwave™ Tumour Specific Electro oration.

Latest news about Scandinavian ChemoTech AB

Scandinavian Chemotech Announces Clinical Trial Progress	07-11	CI
Scandinavian Chemotech AB Provides Sales Results for the Second Quarter of Fiscal Year 2024	06-04	CI
ChemoTech's Animal Care Division Secures Important Order in Germany for a vetIQure TSE system	05-27	CI
Scandinavian ChemoTech AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Scandinavian Chemotech AB Announces Departure of QM & RA Director Eva Ståhl Wernersson	05-01	CI
Scandinavian Chemotech AB Obtains Approval of the Third and Last Patent Application in India	04-22	CI
Scandinavian ChemoTech AB Attains Progress by Obtaining Patent Protection for Two Essential Patents in India	04-10	CI
Scandinavian ChemoTech Secures Order from the Largest European Equine Clinic	03-27	CI
Scandinavian ChemoTech AB's IQwave Receives Certification for Tumour Treatment in Singapore	03-25	CI
Scandinavian ChemoTech AB Signs New Agreement with Chhatrapati Shivaji Subharti Hospital & Medical College	03-20	CI
Scandinavian ChemoTech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
Scandinavian ChemoTech AB Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Scandinavian ChemoTech AB Receives Order for USD 30,000 from One of Its Largest Clients in the United States	02-12	CI
Transcript : Scandinavian ChemoTech AB - Special Call	01-29
Scandinavian ChemoTech's Animal Care Division Receives an Order from A Leading Veterinary Hospital in South Florida, USA	12-15	CI
Scandinavian ChemoTech Expects to Sign Three New Commercial Contracts in Fourth of 2023	12-11	CI
Scandinavian Chemotech Thanks for the Cooperation with Its IR Consultant Who Leaves the Management Team	11-30	CI
Scandinavian ChemoTech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-17	CI
Scandinavian Chemotech AB Animal Care Division Receives Additional Order from Existing Customer	23-10-12	CI
Scandinavian ChemoTech's Subsidiary for Animal Care in the USA Receives Additional Orders for TSE Treatment Kits	23-10-04	CI
Scandinavian Chemotech Foresees Higher Future Revenues After Signing A Third Commercial Contract in India	23-09-29	CI
Scandinavian Chemotech Signs Distribution Agreement for Chile with Lambertis Corporation Sa	23-09-18	CI
Scandinavian ChemoTech AB Expands its Cooperation with Gamma Gurus Pty Ltd in Australia to Include Human Care	23-08-30	CI
Scandinavian ChemoTech AB's Subsidiary VQ Anim Care e Inc. Receives Order Confirmation for a VeterinaryIQure System to Ohio	23-08-18	CI
Scandinavian ChemoTech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI

Chart Scandinavian ChemoTech AB

Duration

Period

More charts

Company Profile

Scandinavian ChemoTech AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused on cancer treatment and manufactures specialized medical equipment. The Company's product IQWave is an electrochemotherapy (ECT) device. The IQWave system enhances the effects of the chemotherapeutic substance by opening up small pores in the tumor cells, giving the injected chemotherapeutic substance (no more than 15 IU of bleomycin) direct access to the DNA of the target cells. Among the product's applications are hypernephroma, kaposi sarcoma, transitional cell carcinoma, head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma. The treatment can be used for cutaneous as well as subcutaneous tumors.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-12 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Scandinavian ChemoTech AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
SCANDINAVIAN CHEMOTECH AB	-31.11%	3.8M
THERMO FISHER SCIENTIFIC	+4.64%	212B
DANAHER CORPORATION	+8.99%	187B
INTUITIVE SURGICAL, INC.	+29.83%	155B
BOSTON SCIENTIFIC CORPORATION	+35.17%	115B
SIEMENS HEALTHINEERS AG	+2.55%	65.5B
EDWARDS LIFESCIENCES CORPORATION	+15.06%	52.87B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-6.47%	45.25B
AGILENT TECHNOLOGIES, INC.	-2.14%	39.7B
GE HEALTHCARE TECHNOLOGIES INC.	+6.88%	37.72B

Other Advanced Medical Equipment & Technology